
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
Click the title above for a link to open the Pharmaceutical Executive February 2024 issue in an interactive PDF format.
almost 3 years ago
Central to the Missionalmost 3 years ago
Two Frameworks for Orphan Drug IDN Launch Planningalmost 3 years ago
Sustainability and Progress Continue to Make Headlines in 2024almost 3 years ago
Building Resiliency: Essential Leadership Principles for 2024almost 3 years ago
Will Strong Early-Year Vibes Translate to More Stabilization Ahead?




